Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(50.0%)
Phase 2
3(50.0%)
6Total
N/A(3)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07573696Phase 2Not Yet Recruiting

Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy

Role: lead

NCT07039656Phase 2Recruiting

Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy

Role: lead

NCT07038460Phase 2Not Yet Recruiting

A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC

Role: lead

NCT04552054Not ApplicableUnknown

Mixed Reality Technique Combined With 3D Printing Navigational Template for Localizing Pulmonary Nodules

Role: lead

NCT04056923Not ApplicableCompleted

3D Printing for Nodule Localization

Role: lead

NCT03230019Not ApplicableUnknown

Two-Lumen Catheterization For Lung Wedge Resection

Role: lead

All 6 trials loaded